TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32744395
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine U300 (IGlarU300)
Study: 35124626
Drug: Motion style
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motion style acupuncture therapy (MSAT) combined with conventional acupuncture therapy (CAT)
Study: 35124626
Drug: Conventional acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional acupuncture therapy (CAT)
Study: 35752582
Drug: Gefapixant 15
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant 15 mg BID
Study: 36879087
Drug: Gefapixant 45
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant 45 mg BID
Study: 32272623
Drug: Solution-focused group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-focused group counseling intervention for five weeks
Study: 33960181
Drug: Oral sensorimotor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sensorimotor stimulation (20 minutes before conventional therapy)
Study: 33960181
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (90 minutes, five times/week for four months)
Study: 33960181
Drug: Oral sensorimotor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sensorimotor stimulation
Study: 32807209
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg orally daily for 14 days
Study: 33888314
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (15 mg/kg, maximum 1 g)
Study: 33340316
Drug: Baloxavir (40/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baloxavir (40/80 mg single dose based on weight)
Study: 36073362
Drug: Tribulus terrestris
Normalized name: TRIBULUS TERRESTRIS
DrugBank: Tribulus terrestris (DB14358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribulus terrestris L.
Study: 32227772
Drug: Clysis therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clysis therapy using glycerin enemas or lactulose oral solution (Control)
Study: 33290437
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor (NGF) injection (n = 20)
Study: 36286979
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg 1 time per day + Alfasoxx 1 sachet qid (intervention group)
Study: 36286979
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg 1 time per day (control group)
Study: 36286979
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (intervention group)
Study: 36286979
Drug: Standard PPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PPI monotherapy (control group)
Study: 33170378
Drug: l-Carnosine (10–15
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Carnosine (10–15 mg/kg in 2 divided doses) plus standard care (occupational and speech therapy)
Study: 33170378
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (occupational and speech therapy)
Study: 36446797
Drug: Neurorehabilitation protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurorehabilitation protocol integrating assisted locomotion with a noninvasive brain-machine interface (L + BMI)
Study: 36446797
Drug: L +
Normalized name: Citracal + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: L + BMI group
Study: 33964828
Drug: Combined eradication
Normalized name: Combinations for eradication of Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined eradication and prokinetic therapy (itoprid hydrochloride 50 mg three times a day)
Study: 33964828
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy only
Study: 32227108
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy clinicians' involvement in research
Study: 35978377
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) intervention for 72 weeks
Study: 32093652
Drug: Ketotifen Fumarate
Normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketotifen Fumarate (KF) 2 mg or 5 mg
Study: 34312798
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide fumarate (TAF) 25 mg/day
Study: 32816829
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (same programme starting 2 months later)
Study: 34997825
Drug: Sodium zirconium
Normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sodium zirconium cyclosilicate (SZC) 10 g
Study: 34750392
Drug: Adjuvant gefitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant gefitinib or chemotherapy based on genomic profiling
Study: 37245533
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (20 IU, twice/day) with dulaglutide (1.5 mg/week)
Study: 37245533
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo with dulaglutide (1.5 mg/week)
Study: 37245533
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (20 IU, twice/day) with placebo
Study: 37245533
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo with placebo
Study: 33581015
Drug: Metformin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin therapy (MT) group
Study: 33581015
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (IT) group
Study: 33392802
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received traditional surgical therapy with primary closure of the surgical area.
Study: 33032612
Drug: LUS or
Normalized name: Aspergillus oryzae
DrugBank: Aspergillus oryzae (DB10448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUS or CXR not suggestive of BN and PCT > 1 ng/mL
Study: 33032612
Drug: LUS or
Normalized name: Aspergillus oryzae
DrugBank: Aspergillus oryzae (DB10448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUS or CXR not suggestive of BN and PCT < 1 ng/mL
Study: 35254932
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of peer comparison and individual audit feedback
Study: 33267837
Drug: Oral clonazepam
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonazepam (0.05 mg/Kg)
Study: 33267837
Drug: Oral lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lorazepam (0.05 mg/Kg)
Study: 36215079
Drug: Transcatheter PFO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter PFO closure plus antithrombotic therapy
Study: 36215079
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy alone
Study: 34519832
Drug: calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: calcium and vitamin D supplements (CaD)
Study: 33162978
Drug: GAD‐alum injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD‐alum injection (4 μg) into lymph nodes + oral Vitamin D (2000 U/d)
Study: 32828678
Drug: Amoxicillin alone
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin alone (70 mg/kg) for five days
Study: 32828678
Drug: Amoxicillin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (70 mg/kg) plus clarithromycin (15 mg/kg) for the initial three days
Study: 34358811
Drug: One-view craniocaudal
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-view craniocaudal (CC) DM-DBT
Study: 34358811
Drug: CC DM-DBT
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CC DM-DBT view
Study: 33022713
Drug: Calcium (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1200 mg/d)
Study: 33515998
Drug: Phytase supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytase supplementation (1 000 U/kg diet) with 1.0, 1.5, or 2.0 g/kg NPP
Study: 33515998
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (phytase-absent) with 2.0, 2.5, or 3.0 g/kg NPP
Study: 32510734
Drug: Single 1.2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1.2-g dose of oral azithromycin
Study: 32510734
Drug: Initial adult
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial adult dose of 500 mg followed by 250 mg per day for 4 days (total cumulative dose of 1.5 g)
Study: 32510734
Drug: For children
Normalized name: Nurofen For Children
Approvals — FDA: no, EMA: no, PMDA: no
Description: For children aged 5 to 18 years, 10 mg/kg on the first day followed by 5 mg/kg for 4 days
Study: 34117375
Drug: Direct supplementation
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct supplementation with Urolithin A (500 mg)
Study: 32167978
Drug: S-ketamine 0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine 0.12 mg/kg/h
Study: 32167978
Drug: S-ketamine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine 0.6 mg/kg/h
Study: 33326257
Drug: Capivasertib (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capivasertib (320 mg twice daily, 4 days on/3 days off)
Study: 35759637
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (1 g)
Study: 35759637
Drug: Subcutaneous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous tranexamic acid (1 g)
Study: 33921829
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum CJLP55 supplement
Study: 33038271
Drug: 1.2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g/kg alcohol dose
Study: 33975304
Drug: Social Nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Nutrition Program (additional 27 g of protein/day and social network intervention)
Study: 32672800
Drug: Ranibizumab, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab, 0.5 mg, plus verteporfin photodynamic therapy (vPDT)
Study: 32672800
Drug: Ranibizumab, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab, 0.5 mg, plus sham PDT
Study: 32349041
Drug: L reuteri
Normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L reuteri DSM 17938
Study: 32349041
Drug: L rhamnosus
Approvals — FDA: no, EMA: no, PMDA: no
Description: L rhamnosus 19070‐2
Study: 32349041
Drug: L reuteri
Normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L reuteri DSM 12246
Study: 32349041
Drug: L helveticus
Approvals — FDA: no, EMA: no, PMDA: no
Description: L helveticus R0052
Study: 32349041
Drug: L rhamnosus
Approvals — FDA: no, EMA: no, PMDA: no
Description: L rhamnosus R0011
Study: 32071176
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo treatment with treatment rationale
Study: 32071176
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo treatment without treatment rationale
Study: 34731434
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection combined with CSEA plus PCEA (AICP group, n=168)
Study: 34080789
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) administration via intravenous and dorsal pancreatic arterial routes
Study: 34080789
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) administration
Study: 36081312
Drug: 6-week tongue
Normalized name: BEEF TONGUE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week tongue elevation training program consisting of anterior tongue elevation strength and endurance tasks with the Iowa Oral Performance Instrument.
Study: 33234910
Drug: Smartphone app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Smartphone app reminder for ASA adherence (81 mg twice daily for 35 days)
Study: 34402328
Drug: Pegfilgrastim administration
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim administration <20 hours after chemotherapy
Study: 34402328
Drug: Pegfilgrastim administration
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim administration ≥24 hours after chemotherapy
Study: 34402328
Drug: Timing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timing of pegfilgrastim administration (earlier or later than 20 hours)
Study: 34402328
Drug: Overall outcomes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall outcomes of pegfilgrastim administration
Study: 32108322
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of plasma gel
Study: 32108322
Drug: Combined plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined plasma gel and dermaroller
Study: 32074767
Drug: Letrozole 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 7.5 mg daily for 3 days
Study: 32074767
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (cetrorelix 0.25 mg subcutaneously daily for 3 days)
Study: 32074767
Drug: Letrozole and
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole and GnRH antagonist
Study: 36180610
Drug: Denosumab (subcutaneous)
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab (subcutaneous) for osteoporosis, 5 years continuous treatment
Study: 36180610
Drug: Denosumab (subcutaneous)
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab (subcutaneous) for osteoporosis
Study: 34561195
Drug: Beta-blockers (yes)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (yes)
Study: 34561195
Drug: Beta-blockers (no)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (no)
Study: 34561195
Drug: Short antiplatelet
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short antiplatelet therapy (1 month)
Study: 34561195
Drug: Prolonged antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged antiplatelet therapy (12 months)
Study: 34678987
Drug: Low-dose neubotulinum
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose neubotulinum toxin A (Neu-BoNT-A)
Study: 34678987
Drug: Low-dose abobotulinum
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose abobotulinum toxin A (Abo-BoNT-A)
Study: 32109743
Drug: Total crystalloid
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total crystalloid volume (TCV) below 3 L
Study: 32109743
Drug: Total crystalloid
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total crystalloid volume (TCV) above 6 L
Study: 33843370
Drug: Tele-problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele-problem-solving therapy (Tele-PST)
Study: 33616641
Drug: Low-dose mycophenolate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose mycophenolate mofetil
Study: 36366886
Drug: Q-122 100
Normalized name: Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-122 100 mg, twice daily for 28 days
Study: 36366886
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for 28 days
Study: 32598700
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy (ET) with the addition of the prebiotic Zakofalk (inulin + butyrate)
Study: 32598700
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy (ET) with the addition of probiotics (lacto- and bifidobacteria)
Study: 32598700
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy (ET) without the addition of pre- or probiotics
Study: 32809153
Drug: Immunotherapy (potential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (potential for use in PD)
Study: 35360106
Drug: Probiotic dose
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic dose 2.5 × 10^9 CFU/day (n = 18)
Study: 35360106
Drug: Probiotic dose
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic dose 1 × 10^10 CFU/day (n = 18)
Study: 33850467
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment at outpatient clinic
Study: 32055717
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy (HF) - 58 Gy/40 fractions, twice daily
Study: 32055717
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy (CF) - 51 Gy/20 fractions, once daily
Study: 32385851
Drug: Long-acting pasireotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting pasireotide 10 or 30 mg every 28 days (minimum/maximum dose: 5/40 mg)
Study: 35176206
Drug: Baloxavir marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baloxavir marboxil 40 mg
Study: 35176206
Drug: Baloxavir marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baloxavir marboxil 80 mg
Study: 35176206
Drug: Baloxavir marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baloxavir marboxil (both doses)
Study: 35809371
Drug: V590 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: V590 (all dose levels)
Study: 34472117
Drug: Vatinoxan (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vatinoxan (0.1 mg/kg)
Study: 32861668
Drug: EX2 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EX2 (5 times a week, twice daily, 50 sessions; n=286)
Study: 32861668
Drug: EX1 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EX1 (5 times a week, once daily, 25 sessions; n=272)
Study: 33852251
Drug: CAL/BDP cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAL/BDP cream
Study: 34244250
Drug: oXiris membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: oXiris membrane used on the Prismaflex device at blood pump flow of 450 mL/min during cardiac surgery under CPB
Study: 35294415
Drug: Vonoprazan 20mg
Normalized name: VONOPRAZAN 20MG TAB
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan 20mg once-daily
Study: 35294415
Drug: Lansoprazole 30mg
Normalized name: LANSOPRAZOLE 30MG CAP,SA
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole 30mg once-daily
Study: 34085549
Drug: Intradermal mesotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal mesotherapy
Study: 33276738
Drug: HCV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV treatment adherence
Study: 33276738
Drug: HCV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV treatment completion
Study: 33276738
Drug: Cigarette smoking
Normalized name: Cigarette smoking tobacco
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette smoking after HCV treatment
Study: 35588897
Drug: Olpasiran 10
Normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpasiran 10 mg q12 weeks
Study: 35588897
Drug: Olpasiran 75
Normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpasiran 75 mg q12 weeks
Study: 35588897
Drug: Olpasiran 225
Normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpasiran 225 mg q12 weeks
Study: 35588897
Drug: Olpasiran 225
Normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpasiran 225 mg q24 weeks
Study: 33416226
Drug: Sequential Splints
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Splints Method